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Abstract
Background: Hepatitis B (HB) prevention in the low-endemicity province of Quebec Canada, (population: ~8.2 million;
birth cohort ~85,000/year), includes two decades of pre-adolescent school-based immunization, as well as catch-up
immunization for those born since 1983 and pre-natal maternal HBsAg screening. To estimate the potential added
benefit of routine infant HB immunization, notifiable disease reports were analyzed (1990–2013). Clinical and demographic
information about cases was retrieved from standard questionnaires used by local public health units to investigate HB cases.
Methods: The Quebec provincial registry of notifiable diseases was used to identify confirmed HB cases reported between
1990 and 2013. Clinical and demographic information on cases was retrieved from the standard questionnaires used by local
public health units to investigate reported HB cases.
Results: Between 1990–2013, acute-HB incidence per 100,000 population decreased by 97 % from 6.5 to 0.2. Compared to
1990, incidence fell from 0.6 to zero since 2010 among children ≤9 years of age (yoa), from 3.2 to zero since 2007 in those
10–19 yoa, and from 15 to zero in 2013 among adults 20–29 yoa, previously the age group of highest incidence (all p < 0.0001).
During the same period, the newly-reported chronic HB rate per 100,000 decreased by 66 % from 17.7 to 6.1 (p < 0.0001), with
a reduction of 92 % (2.4 to 0.2;p < 0.001) in children ≤9 yoa and 83 % (7.2 to 1.2;p= 0.003) in those 10–19 yoa. The incidence of
unspecified HB cases did not decrease significantly overall (5.9 vs. 5.4; p= 0.24), in children≤ 9 yoa (0.3 vs. 0.2;p= 0.70) or 10–19
yoa (1.6 vs. 1.5;p= 0.45).
Overall, 91 % of cases ≤19 yoa were immigrants likely infected before arrival in Canada. Among those ≤9 yoa, there were 9
acute-HB case reports between 2005 and 2013, of whom 8 were not preventable by infant immunization.
Conclusions: Two decades of school-based immunization coupled with prenatal screening achieved striking
reduction in disease burden in the low-endemicity province of Quebec, Canada. The oldest cohorts targeted by
catch-up campaigns are now beyond the average age at childbirth so that neo-natal transmission and the
potential incremental benefit of infant immunization will likely further diminish.
Background
While most countries have universal hepatitis B (HB)
immunization programs targeting infants, eight of the 10
provinces of Canada initially opted for school-based
pre-adolescent or adolescent HB immunization programs
[1, 2]. In the province of Quebec (population: ~8.2million;
birth cohort ~85,000/year), the publicly-funded HB pre-
vention program commenced with immunization of high-
risk individuals in 1983 (including infants in households
with known HB carriers), was expanded to include routine
pre-natal HBsAg screening in 1989, and further expanded
to provide universal grade 4 elementary school-based HB
immunization to pre-adolescents 8–10 years of age (yoa) in
1994 [2, 3]. A catch-up HB immunization campaign for high
school students was conducted in 1999 [2]. Between 1994
and 2007, students were immunized with a three-dose
schedule (0, 1, 6 months) with Engerix-B or Recombivax-
HB at pediatric dosage and since 2008 a two-dose schedule
of Twinrix-Junior (at 0, 6 months) has been used [4]. This
school-based HB immunization program in Quebec has
steadily delivered vaccine to ~85 % of students annually
and in combination with the catch-up campaign, has
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provided protection to the vast majority of Quebec
students born since 1983 [3].
Evaluation of the Quebec school-based HB immunization
program one decade after its implementation showed dra-
matic effects: reported incidence of acute cases in Quebec
decreased by 79 % overall and by 91 % in pre-adolescents
and adolescents 10–19 yoa [5]. These trends were similar
to those observed in another large Canadian province with
an adolescent program [6]. While such early program eval-
uations showed striking population benefit, it was neverthe-
less reasoned that a universal infant HB immunization
program could prevent residual cases in young children ≤9
yoa, particularly since infants are at highest risk of chronic-
HB infection and acute-HB in young children may
otherwise be missed because more often asymptomatic [7].
Further, routine three-dose immunization coverage with
pediatric pentavalent vaccine (DTaP-Polio-Hib) exceeds
95 % so that switching to the available hexavalent vaccine
additionally inclusive of HB could improve coverage and
reduce injections related to the school program. Here, we
report follow-up analyses using notifiable disease reports
to assess potential epidemiologic benefit of a universal
infant immunization program after two decades of a
pre-adolescent school-based program in Quebec, Canada.
Methods
The Quebec provincial registry of notifiable diseases was
used to identify confirmed HB cases reported between
1990 and 2013. As per the Canadian national case
definition [8], acute HB cases were defined as patients test
positive for HBsAg or anti-HBcIgM in the context of
compatible clinical history or probable exposure, or an
HBsAg-positive newborn of an HBsAg-positive mother.
Chronic HB cases were defined as patients with HBsAg or
viral DNA detected at an interval of at least 6 months or
detection of HBsAg in the absence of anti-HBcIgM and
no acute-HB clinical symptoms. Unspecified cases were
HBsAg or viral DNA positive individuals for which avail-
able information was insufficient to classify them as either
acute or chronic. Clinical and demographic information
on cases was retrieved from the standard questionnaires
used by local public health units to investigate reported
HB cases. This surveillance study using denominalized in-
formation was legally mandated by the provincial officer
of public health of Quebec according to the Public Health
Act and research ethics committee approval was not
required. Information on epidemiology of hepatitis B in
the province of Quebec for the period of 2000–2010 is
also available at: http://www.inspq.qc.ca/pdf/publications/
1847_Maladies_Vaccination_Declaration_Obligatoire.pdf.
All statistical analyses were performed using the Statis-
tical Analysis System (SAS Institute Inc, Cary, NC, version
9.4). Chi-square tests were used for the assessment of HB
trends from 1990 to 2013 and differences were considered
significant at p<0.05. The hepatitis B incidence rates and
the rates of potentially preventable cases of disease were
calculated by dividing the number of new cases by the
population by age group throughout each year, expressed
as case reports per 100,000 population.
Results
Notifiable disease trends: acute and chronic HB report
rates, 1990–2013
Between 1990–2013, the overall incidence of acute-HB
cases per 100,000 decreased by 97 % from 6.5 to 0.2
(p<0.0001), (Fig. 1). In children ≤9 yoa, the acute-HB in-
cidence decreased from 0.6 in 1990 to no cases since
2010 (p < 0.0001). In those 10–19 yoa, the incidence of
3.2 in 1990 also decreased to zero since 2007 (p <
0.0001). Finally, in adults 20–29 yoa, the incidence of 15
per 100,000 in 1990, formerly the highest of all age
groups, also fell to zero in 2013 (p < 0.0001).
During the same period, the overall rate of newly-
reported chronic-HB cases per 100,000 decreased by
66 % from 17.7 to 6.1 (p < 0.0001), with a reduction of
92 % (2.4 to 0.2;p < 0.001) in children ≤ 9 yoa and 83 %
(7.2 to 1.2;p = 0.003) in those 10–19 yoa. The rate of un-
specified case reports showed an initial downward then
upward trend during the study period. However, rates
were low and stable throughout in children ≤ 9 yoa (0.3
vs. 0.2;p = 0.70) and 10–19 yoa (1.6 vs. 1.5;p = 0.45) old
(Fig. 1). The upward trend in unspecified case reports
since 2004 was among adults ≥20 yoa and primarily 30–
39 yoa (Fig. 1).
Acute-HB case reports – potential for prevention through
infant immunization
Among children ≤9 yoa, there were 9 acute-HB case
reports during the 2005–2013 period, all before 2010 and
of whom 8 would not have been preventable by routine
universal infant immunization. Five children had been
adopted from HB-endemic countries and were already
infected upon arrival in Canada. Three children were born
in Quebec from HBsAg-positive mothers: two had re-
ceived immunoglobulin at birth and 3 or 4 doses of
vaccine according to the recommended schedule. The
parents of the third child refused prenatal screening; the
mother was identified to be HBsAg-positive 2 months
post-delivery and the child was diagnosed with HB a few
months after birth. The final acute HB case was born in
another Canadian province and was diagnosed at pre-
school age. The mother was born in a highly-endemic
country but her HBsAg status and the child’s age upon ar-
rival in Quebec were unknown. Assuming that this latter
case was preventable, then over and above the existing
program, an infant immunization program could have
spared 0.0249 acute-HB cases per 100,000 person-years
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(CI:0.0248-0.0251) in children ≤9 yoa between 2005 and
2009 and none between 2010 and 2013.
There were two acute-HB cases reported in individ-
uals 10–19 yoa between 2005 and 2013; both occurred
before 2008. The first was an unvaccinated homosexual
boy born in Quebec; the second was a drug user with
no information on country of birth or vaccination
status. In addition to school-based HB vaccine-
eligibility, these two individuals would have been eli-
gible for immunization on the basis of high-risk
behaviours but assuming infant immunization may have
spared their infection, this would correspond to an add-
itional preventable rate of 0.0654/100,000 person-years
(CI:0.0651-0.0657) between 2005 and 2007 in that age
group, and none between 2008 and 2013.
Overall, in addition to the existing program, an infant
immunization program could have prevented 0.0335
(95 % CI: 0.0334-0.0336) acute-HB cases per 100,000
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Fig. 1 Reported rate per 100 000 person-years of acute, chronic and unspecified hepatitis B cases
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Chronic-HB and unspecified cases – risk factors
With no acute-HB case reported in children ≤9 yoa
since 2010, we limited the analysis of risk factors among
chronic cases to the period spanning 2005–2009.
Among the 38 chronic-HB cases reported in children
≤9 yoa, 34 (89 %) were born outside Quebec, three were
born in Quebec and one lacked place-of-birth informa-
tion. The three Quebec-born children had known
HBsAg-positive mothers, received adequate vaccination
and immunoglobulin at birth and were not preventable.
Among the 34 (89 %) immigrant cases, 13 were already
infected upon arrival in Canada or diagnosed with
chronic-HB during the first 12 months thereafter; 9 had
unknown HBsAg status at arrival but were born from a
known HBsAg-positive mother; and one was fully vacci-
nated before arrival. For the other 11 cases there was
insufficient information to explain when and how they
became infected.
In the 10–19 yoa group, there were 118 chronic-HB
cases reported between 2005 and 2009. Of these, 9 cases
were born in Quebec and 109 cases (92 %) were born
outside Quebec (n = 84) or with unknown place of birth
(n = 25). Among individuals born in Quebec, 2 were
born to HBsAg-positive mothers, 2 had HBsAg carriers
among their family members, 2 reported unsafe sex, 2
had parents born in an endemic country with unknown
HB status and one did not report any risk factor. The
two cases born to HBsAg-positive mothers were prob-
ably infected at birth and would likely not have been
prevented by an infant program starting at 2 months of
age. Among the other 109 chronic-HB cases, 80 (68 %)
were born in a high-endemicity country, 2 had HBsAg
carriers among their family members, 2 were born to an
HBsAg-positive mother, and 1 reported sexual aggres-
sion as a potential cause of infection.
In addition, there were 15 case reports in people 10–
19 yoa with unspecified acute or chronic HB status, 5 of
whom were born in a high-endemicity country and
another whose parents were born in an endemic
country. For the other 9 unspecified cases, there was no
information on country of birth or other risk factors.
Globally, among the 182 cases reported in those ≤19
yoa, 133 cases were born outside Quebec, 122 (91 %,
CI:87 %-96 %) of whom were born in an endemic
country.
Discussion
This study using HBV notifiable disease statistics and
case reports from a low-endemicity country, reveals the
remarkable success of two decades of pre-adolescent
immunization coupled with prenatal HBsAg screening in
controlling HB not only in adolescents but also in chil-
dren ≤9 yoa and adults 20–29 yoa. We measured 97 %
reduction in acute-HB cases in the population overall
since 1990, and an absence of acute cases in children ≤9
yoa since 2010, in adolescents 10–19 yoa since 2007,
and in adults 20–29 yoa, formerly with the highest inci-
dence, in 2013. In that context, it is difficult to assert
that further program change is likely to bring important
epidemiologic benefit.
During the study period, the rate of chronic-HB cases
reported also dramatically decreased (by 92 % in chil-
dren ≤9 yoa and 83 % in those 10–19 yoa). As the vast
majority of chronic cases were born in highly-endemic
countries, this large reduction is most likely attributable
to universal infant immunization programs currently in
place elsewhere in most high-endemicity countries,
reducing chronic carriage in young immigrants and
thereby also the risk of HB transmission during early
childhood in Quebec. The potential for prevention of
these chronic cases through infant immunization in
Quebec would have been limited as most were born in
endemic countries and likely infected before arriving in
Quebec. Should some immigrant cases have acquired
their infection after their arrival in Quebec, as they
were up to 19 yoa, they could have been prevented only
if an infant program had been in place since the early
1990s. Cases potentially preventable through infant
immunization in 2014 are expected to be even lower
recognizing no acute cases have been identified in chil-
dren ≤9 yoa since 2010. Whether such further decre-
ments in disease burden warrant program change
ultimately depends upon operational, health care, soci-
etal and cost considerations but is less evident based on
epidemiologic indicators.
This study has some limitations. It was based on pas-
sive surveillance reports of notifiable diseases with im-
perfect sensitivity likely to underestimate the true
incidence of HB, particularly among young children with
a greater frequency of mild or asymptomatic acute infec-
tion. While diagnostic approaches and clinician testing
behaviours in response to patients presenting with acute
viral hepatitis are unlikely to have changed substantially
over the study period, we cannot exclude some varia-
tions in the detection of HB over time. Additionally, HB
reporting has been mandatory for physicians and labora-
tories for several decades [5] and observed trends in
acute cases are likely to be robust, reflecting extensive
reduction in transmission and risk. While the unspeci-
fied case category may include acute cases, this would
not change overall conclusions. The number of unspeci-
fied cases reported annually in the overall population
varied from year-to-year without an evident or statisti-
cally significant trend. Unspecified cases were rare in
those ≤19 yoa and the upward trend since 2004 was
driven mainly by adults 30–39 yoa who were not
vaccine-eligible by age. Finally, these results were ob-
tained in a low-endemicity country and should not be
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extrapolated to moderate- or high-endemicity areas or
those without HBsAg prenatal screening. However, as
18 % of the Quebec population is born outside Canada
[9], including 54 % of immigrants from Asia, Africa or
the Middle East [10], these results may nevertheless be
relevant to other jurisdictions with low endemicity but
a substantial proportion of immigrants from highly-
endemic regions.
Conclusion
In summary, two decades of pre-adolescent school-based
immunization coupled with prenatal HBsAg screening has
achieved striking reduction in population HB disease bur-
den. Furthermore, the oldest cohorts targeted by catch-up
campaigns are now beyond the average childbearing age
(30 years) and the age at which the greatest number of
births occur (28 years) in Quebec; as such, neo-natal
transmission is anticipated to further diminish.
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